Gland Pharma Holds 48th AGM, Executive Chairman Reviews FY26 Performance
Gland Pharma's 48th AGM was held on August 25, 2026. The company reported FY26 consolidated revenue of ₹64,307 million, up 14% YoY. EBITDA was ₹16,295 million (25% margin), up 28% YoY. PAT was ₹10,273 million, up 47% YoY. Cenexi revenues grew 25% to ₹18,693 million.
The AGM report details the company's full-year financial performance, strategic direction, and operational highlights, which are material information for investors and stakeholders. The positive financial results and forward-looking strategies are likely to significantly influence investor sentiment and the company's stock performance.
The announcement highlights strong financial performance for FY26 with significant growth in revenue, EBITDA, and PAT, alongside a turnaround at Cenexi. The Executive Chairman's address conveys optimism about future growth strategies and the company's strong market position.
Gland Pharma Limited conducted its 48th Annual General Meeting (AGM) on Tuesday, August 25, 2026, via Video Conferencing / Other Audio-Visual Means (OAVM).
During the AGM, Executive Chairman Mr. Srinivas Sadu presented the company's performance for the fiscal year 2025-26. Gland Pharma reported a consolidated revenue of ₹64,307 million and an EBITDA of ₹16,295 million, achieving a 25% EBITDA margin, which reflects a 275 basis points year-on-year improvement. Profit After Tax (PAT) rose by 47% to ₹10,273 million, with a PAT margin of 16%. The company also highlighted a significant turnaround at Cenexi, with revenues growing by 25% to ₹18,693 million, leading to substantial EBITDA improvement.
The Chairman also elaborated on the company's strengths, including its manufacturing capabilities with a capacity of approximately 1.7 billion units per year across 11 facilities, a strong compliance track record with no USFDA warning letters, and a diversified business model. The company's R&D efforts are robust, with 388 cumulative ANDA filings in the US (337 approved, 51 pending) and a pipeline of 24 complex and 15 co-development products. The company invested ₹2,230 million in R&D during the year.
Key strategic levers for future growth were outlined, focusing on strengthening the CDMO business, widening the complex injectables portfolio, investing in capacity expansion, leveraging Cenexi in Europe, driving geographic expansion, and advancing ESG initiatives. The company emphasized its commitment to sustainability, detailing environmental efforts like solar infrastructure investments and water conservation, social initiatives with 21 CSR projects reaching over 61,000 beneficiaries, and maintaining high governance standards.
Geographically, the US remained a key growth engine with revenue of ₹34,214 million (up 13%), while Europe showed strong performance with revenue of ₹14,035 million (up 34%). The company also detailed its innovation platform and advanced its complex product portfolio, including six complex product launches and 15 products under co-development. The company concluded with an optimistic outlook on future growth, driven by its resilient business model, talented workforce, and strong stakeholder trust.
A plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.